Concepedia

Christopher Hagenstad

CH

Statistics

Publications

6

Citations

1.6K

H-Index

6

Active since

2006

Affiliations

University of California, Los Angeles(Current)

Research International (United States)

Christopher Hagenstad is an author at University of California, Los Angeles specializing in cancer therapeutics, oncology, and medicine.

Top concepts

Publications per year

2006–2018

6

Publications

6

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

J. Randolph Hecht, Edith P. Mitchell, Tarek Chidiac et al. · Journal of Clinical Oncology · 2008 · 851 citations · Full text

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 568 citations · Full text

, , +5

Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer

Johanna C. Bendell, John Nemunaitis, S. Vukelja et al. · Journal of Clinical Oncology · 2011 · 105 citations · Full text

Final Results of a Phase II Trial Evaluating Trastuzumab and Bevacizumab as First Line Treatment of HER2-Amplified Advanced Breast Cancer.

Sara A. Hurvitz, Mark D. Pegram, L. S. Lin et al. · Cancer Research · 2009 · 54 citations

, , +12

A phase II evaluation of the combination of paclitaxel protein-bound and carboplatin in the first-line treatment of advanced non-small cell lung cancer (NSCLC)

J. P. Allerton, Christopher Hagenstad, R. Timothy Webb et al. · Journal of Clinical Oncology · 2006 · 14 citations

, , +15

1–5 of 6